KRAS and neoplasm: Using the IHC method on tumor front and center, the authors show that KRAS-mutated tumors have significantly lower infiltration of CD8+ cytotoxic T cells and T-bet+ Th1 cells compared with KRAS wild-type cases, particularly at the tumor front, where immune-tumor interactions are most critical.